Apomorphine for Parkinson's disease: pharmacologic and clinical considerations

IntroductionIn Parkinson's disease, dopamine depletion in the basal ganglia leads to symptoms including bradykinesia, gait abnormalities, and cognitive impairment. Even with treatment, the disease course leads to decreases in the amount of dopamine produced and released into the synapse. As dopamine production falls and the treatment course is insufficient to match the metabolic supply and demand, acute 'off' periods develop that cause reemergence of symptoms. Apomorphine is used to reverse these 'off' periods and restore function in patients with Parkinson's. This review will provide clinicians a concise article to read to learn more about apomorphine and its appropriate utilization.Areas coveredThe research discussed is focused on the history, pharmacokinetics, and mechanism of action of Apomorphine. Its utilization as a treatment for Parkinson's Disease and its comparison to currently utilized drugs is also discussed in this review. We focused on articles published on PubMed and Google Scholar within the last 10 years, but in some instances had to go as far back as 1951 to include early articles published about apomorphine.Expert opinionThe expert opinion section focuses on the ways in which apomorphine could be administered in the future to better promote utilization and increase tolerability.

Automated summary

Parkinson's disease is characterized by dopamine depletion in the basal ganglia, leading to symptoms such as bradykinesia, gait abnormalities, and cognitive impairment. Apomorphine is used to reverse acute "off" periods during the disease course and restore function in patients. This review provides a concise article discussing the history, pharmacokinetics, mechanism of action, and utilization of apomorphine as a treatment for Parkinson's disease.